Valneva stock, leading the SBF 120, approaches its resistance at €3.07
The Lyon-based pharmaceutical company is posting the best performance on the SBF 120 this Wednesday, in a market broadly oriented downwards, marked by military escalation between Iran and the United States weighing on European indices. The gain brings the stock to the level of its resistance at €3.07, in the context of a spectacular monthly rebound.
Leading the SBF 120 with a gain of 4.42%, Valneva approaches its resistance at €3.07
Valneva gains 4.42% to €2.93 in trading, rising to the top position on the SBF 120 while the index falls 0.42% in a tense geopolitical context. The stock is now just a few cents away from its resistance at €3.07, a threshold that, if broken, would open territory that has remained unoccupied for several months. Above its twenty-day and fifty-day moving averages (at €2.70 and €2.40 respectively), the stock is benefiting from solid technical configuration on these short and medium-term horizons.
Only the 200-day MA at €3.19 remains above the current price; this figure reminds us that the underlying trend over one year remains unfavorable, with Valneva having lost nearly 22% over the past twelve months. The RSI at 60 reflects bullish momentum without excess, far from overbought zones, leaving room before any upside technical tension configuration.
A monthly rebound of 36% amid sharp regression in short positions
Wednesday's advance is part of a remarkable monthly dynamic: the stock accumulates more than 36% over the month, after going through a phase of high volatility that saw sharp declines in late August. This recovery is accompanied by a decline in short positions: according to reported declarations, three funds totaled 2.70% of capital sold short as of August 28, compared with 3.38% a month earlier, representing a decline of 0.68 percentage points. This gradual withdrawal from shorts, while not massive, suggests that institutional downward pressure has eased in recent weeks, a movement consistent with the stock's rebound.
On the substance, the first half 2026 accounts published on August 13 had highlighted a net loss deepened to €63.3 million, but the group had confirmed its annual targets and highlighted strengthened cash reserves. Furthermore, the European Medicines Agency accepted to examine the marketing authorization application file for the Lyme disease vaccine candidate developed with Pfizer, a regulatory matter that remains one of the group's strategic priorities. The resistance at €3.07 is now the immediate benchmark to watch for the remainder of trading.
